Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis.

Authors

Tobias Poch, Jonas Bahn, Christian Casar, Jenny Krause, Ioannis Evangelakos, Hilla Gilladi, Lilly K Kunzmann, Alena Laschtowitz, Nicola Iuso, Anne-Marie Schäfer, Laura A Liebig, Silja Steinmann, Marcial Sebode, Trine Folseraas, Lise K Engesæter, Tom H Karlsen, Andre Franke, Norbert Hubner, Christian Schlein, Eithan Galun, Samuel Huber, Ansgar W Lohse, Nicola Gagliani, Dorothee Schwinge, Christoph Schramm

Year of publication

2024

Journal

Cell Rep Med

Volume

5

Issue

7

ISSN

2666-3791

Impact factor

16.988

Abstract

Primary sclerosing cholangitis (PSC) is an immune-mediated liver disease of unknown pathogenesis, with a high risk to develop cirrhosis and malignancies. Functional dysregulation of T cells and association with genetic polymorphisms in T cell-related genes were previously reported for PSC. Here, we genotyped a representative PSC cohort for several disease-associated risk loci and identified rs56258221 (BACH2/MIR4464) to correlate with not only the peripheral blood T cell immunophenotype but also the functional capacities of naive CD4+ T (CD4+ TN) cells in people with PSC. Mechanistically, rs56258221 leads to an increased expression of miR4464, in turn causing attenuated translation of BACH2, a major gatekeeper of T cell quiescence. Thereby, the fate of CD4+ TN is skewed toward polarization into pro-inflammatory subsets. Clinically, people with PSC carrying rs56258221 show signs of accelerated disease progression. The data presented here highlight the importance of assigning functional outcomes to disease-associated genetic polymorphisms as potential drivers of diseases.